Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human PD-L1 Antibody, R&D Systems™

Mouse Monoclonal Antibody
Supplier: R&D Systems MAB1561
This item is not returnable.
View return policy
Description
PD-L1 Monoclonal specifically detects PD-L1 in Human samples. It is validated for Flow Cytometry, Immunohistochemistry, CyTOF-ready.Specifications
PD-L1/B7-H1 | |
Monoclonal | |
LYOPH | |
Flow Cytometry 0.25 ug/10^6 cells, Immunohistochemistry 8-25 ug/mL, CyTOF-ready | |
Q9NZQ7 | |
CD274 | |
Mouse myeloma cell line NS0-derived recombinant human PD-L1/B7-H1 Phe19-Thr239 Accession # Q9NZQ7 | |
100 μg | |
Primary | |
Detects human PD-L1/B7-H1 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) B7-1, -2, -H2, -H3, -H3b, -H4, rhPD-L2, recombinant mouse B7-H1, recombinant rat (rr) B7-1, or rrB7-2 is observed. | |
Human | |
Purified |
Flow Cytometry, Immunohistochemistry, CyTOF | |
130021 | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
Avelumab, B7-H, B7H1, B7-H1, B7H1PDCD1L1, CD274, CD274 antigenMGC142294, CD274 molecule, PDCD1L1, PDCD1LG1, PDCD1LG1MGC142296, PDL1, PD-L1, PD-L1B7 homolog 1, PDL1PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1 | |
Mouse | |
Protein A or G purified from hybridoma culture supernatant | |
RUO | |
29126 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction